Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Highly Accessed Editorial

Remission makes its way to rheumatology

Tuulikki Sokka1* and Heidi Mäkinen2

Author Affiliations

1 Jyväskylä Central Hospital, Keskussairaalantie 19, 40620 Jyväskylä, Finland

2 Tampere University Hospital, Teiskontie 35, 33500 Tampere, Finland

For all author emails, please log on.

Arthritis Research & Therapy 2010, 12:129  doi:10.1186/ar3059


See related research by Saber et al., http://arthritis-research.com/content/12/3/R94

Published: 14 July 2010

Abstract

Remission was a rare event, even in the most advanced rheumatology clinics, until recent times. However, in the early 1990s, it was chosen as the treatment goal and the primary outcome measure for the Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo) trial, which can be considered the beginning of remission's way to rheumatology. In addition to remission in patients with rheumatoid arthritis, remission in patients with psoriatic arthritis is now being studied, although remission criteria for psoriatic arthritis have yet to be defined. Better treatment results with more active treatment strategies and availability of biologic agents motivate rheumatologists to monitor their patients as part of usual rheumatology care.